Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers. PRLR Protein, Canine, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 53.89 kDa and the accession number is XM_038663941.1.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
100 μg | 約5 days | ¥ 107,000 |
500 μg | 約5 days | ¥ 424,500 |
1 mg | 約5 days | ¥ 711,500 |
説明 | Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers. PRLR Protein, Canine, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 53.89 kDa and the accession number is XM_038663941.1. |
Species | Canine |
Expression Host | HEK293 Cells |
Tag | C-hFc |
Accession Number | XM_038663941.1 |
別名 | PRL-R, Prolactin R, MFAB, HPRL |
Construction | Gln25-Thr235 |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
分子量 | 53.89 kDa (predicted). Due to glycosylation, the protein migrates to 65-70 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted protein solutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. |
Research Background | Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
PRLR Protein, Canine, Recombinant (hFc) PRL-R Prolactin R MFAB HPRL recombinant recombinant-proteins proteins protein